These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1292 related articles for article (PubMed ID: 24018362)
21. Transferrin-conjugated magnetic silica PLGA nanoparticles loaded with doxorubicin and paclitaxel for brain glioma treatment. Cui Y; Xu Q; Chow PK; Wang D; Wang CH Biomaterials; 2013 Nov; 34(33):8511-20. PubMed ID: 23932498 [TBL] [Abstract][Full Text] [Related]
22. A transferrin variant as the targeting ligand for polymeric nanoparticles incorporated in 3-D PLGA porous scaffolds. Lopes AM; Chen KY; Kamei DT Mater Sci Eng C Mater Biol Appl; 2017 Apr; 73():373-380. PubMed ID: 28183621 [TBL] [Abstract][Full Text] [Related]
23. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin. Li X; Ding L; Xu Y; Wang Y; Ping Q Int J Pharm; 2009 May; 373(1-2):116-23. PubMed ID: 19429296 [TBL] [Abstract][Full Text] [Related]
25. Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel. Feng SS; Mei L; Anitha P; Gan CW; Zhou W Biomaterials; 2009 Jul; 30(19):3297-306. PubMed ID: 19299012 [TBL] [Abstract][Full Text] [Related]
26. The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment. Yang M; Li J; Gu P; Fan X Bioact Mater; 2021 Jul; 6(7):1973-1987. PubMed ID: 33426371 [TBL] [Abstract][Full Text] [Related]
27. Anti-tumor activity of paclitaxel through dual-targeting carrier of cyclic RGD and transferrin conjugated hyperbranched copolymer nanoparticles. Xu Q; Liu Y; Su S; Li W; Chen C; Wu Y Biomaterials; 2012 Feb; 33(5):1627-39. PubMed ID: 22118775 [TBL] [Abstract][Full Text] [Related]
28. Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles. Bartlett DW; Davis ME Bioconjug Chem; 2007; 18(2):456-68. PubMed ID: 17326672 [TBL] [Abstract][Full Text] [Related]
29. Tumor cell targeting of transferrin-PEG-TNF-alpha conjugate via a receptor-mediated delivery system: design, synthesis, and biological evaluation. Jiang YY; Liu C; Hong MH; Zhu SJ; Pei YY Bioconjug Chem; 2007; 18(1):41-9. PubMed ID: 17226956 [TBL] [Abstract][Full Text] [Related]
30. PEGylated J591 mAb loaded in PLGA-PEG-PLGA tri-block copolymer for targeted delivery: in vitro evaluation in human prostate cancer cells. Moffatt S; Cristiano RJ Int J Pharm; 2006 Jul; 317(1):10-3. PubMed ID: 16713147 [TBL] [Abstract][Full Text] [Related]
31. Ligand-targeted theranostic nanomedicines against cancer. Yao VJ; D'Angelo S; Butler KS; Theron C; Smith TL; MarchiĆ² S; Gelovani JG; Sidman RL; Dobroff AS; Brinker CJ; Bradbury ARM; Arap W; Pasqualini R J Control Release; 2016 Oct; 240():267-286. PubMed ID: 26772878 [TBL] [Abstract][Full Text] [Related]
32. Paclitaxel loaded folic acid targeted nanoparticles of mixed lipid-shell and polymer-core: in vitro and in vivo evaluation. Zhao P; Wang H; Yu M; Liao Z; Wang X; Zhang F; Ji W; Wu B; Han J; Zhang H; Wang H; Chang J; Niu R Eur J Pharm Biopharm; 2012 Jun; 81(2):248-56. PubMed ID: 22446630 [TBL] [Abstract][Full Text] [Related]
33. Ligand-based targeted delivery of a peptide modified nanocarrier to endothelial cells in adipose tissue. Hossen MN; Kajimoto K; Akita H; Hyodo M; Ishitsuka T; Harashima H J Control Release; 2010 Oct; 147(2):261-8. PubMed ID: 20647023 [TBL] [Abstract][Full Text] [Related]
34. Using doxorubicin and siRNA-loaded heptapeptide-conjugated nanoparticles to enhance chemosensitization in epidermal growth factor receptor high-expressed breast cancer cells. Liu CW; Lin WJ J Drug Target; 2013 Sep; 21(8):776-86. PubMed ID: 23829387 [TBL] [Abstract][Full Text] [Related]
35. Self-aggregated pegylated poly (trimethylene carbonate) nanoparticles decorated with c(RGDyK) peptide for targeted paclitaxel delivery to integrin-rich tumors. Jiang X; Sha X; Xin H; Chen L; Gao X; Wang X; Law K; Gu J; Chen Y; Jiang Y; Ren X; Ren Q; Fang X Biomaterials; 2011 Dec; 32(35):9457-69. PubMed ID: 21911250 [TBL] [Abstract][Full Text] [Related]
36. Peptide ligand-modified nanomedicines for targeting cells at the tumor microenvironment. David A Adv Drug Deliv Rev; 2017 Sep; 119():120-142. PubMed ID: 28506743 [TBL] [Abstract][Full Text] [Related]
37. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. Wang H; Zhao Y; Wu Y; Hu YL; Nan K; Nie G; Chen H Biomaterials; 2011 Nov; 32(32):8281-90. PubMed ID: 21807411 [TBL] [Abstract][Full Text] [Related]
38. Targeting Nanomedicines to Prostate Cancer: Evaluation of Specificity of Ligands to Two Different Receptors In Vivo. Pearce AK; Fuchs AV; Fletcher NL; Thurecht KJ Pharm Res; 2016 Oct; 33(10):2388-99. PubMed ID: 27225496 [TBL] [Abstract][Full Text] [Related]
39. Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect. Zhan C; Gu B; Xie C; Li J; Liu Y; Lu W J Control Release; 2010 Apr; 143(1):136-42. PubMed ID: 20056123 [TBL] [Abstract][Full Text] [Related]
40. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice. Gabizon A; Horowitz AT; Goren D; Tzemach D; Shmeeda H; Zalipsky S Clin Cancer Res; 2003 Dec; 9(17):6551-9. PubMed ID: 14695160 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]